Intravenous-to-oral switch in anticancer chemotherapy: A focus on docetaxel and paclitaxel

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 1, 2010, Pages 126-129

  Koolen, S L W ^a,b   Beijnen, J H ^a,b,c   Schellens, J H M ^a,b,c  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; DOCETAXEL; PACLITAXEL; RITONAVIR;

BONE MARROW SUPPRESSION; BREAST METASTASIS; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; HUMAN; LUNG NON SMALL CELL CANCER; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; STOMACH CANCER; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 CYP3A; HUMANS; INFUSIONS, INTRAVENOUS; PACLITAXEL; TAXOIDS;

EID: 72849148183     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.233     Document Type: Short Survey

References (37)

1. Rowinsky, E.K. & Donehower, R.C. Paclitaxel (taxol). N. Engl. J. Med. 332, 1004-1014 (1995).
2. Schuette, W. et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J. Clin. Oncol. 23, 8389-8395 (2005).
3. Green, M.C. et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks J. Clin. Oncol. 23, 5983-5992 (2005).
4. Benelli, R., Monteghirfo, S., Balbi, C., Barboro, P. & Ferrari, N. Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player. Int. J. Cancer 124, 2989-2996 (2009).
5. Kerbel, R.S. & Kamen, B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 4, 423-436 (2004).
6. Grant, D.S., Williams, T.L., Zahaczewsky, M. & Dicker, A.P. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int. J. Cancer 104, 121-129 (2003).
7. Juliano, R.L. & Ling, V. a surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455, 152-162 (1976).
8. Gottesman, M.M., Fojo, T. & Bates, S.E. Multidrug resistance in cancer: role of aTP-dependent transporters. Nat. Rev. Cancer 2, 48-58 (2002).
9. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M.M., Pastan, I. & Willingham, M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 84, 7735-7738 (1987).
10. Schinkel, A.H. et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a defciency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77, 491-502 (1994).
11. Van asperen, J., Schinkel, A.H., Beijnen, J.H., Nooijen, W.J., Borst, P. & van Tellingen, O. altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-defcient Mice. J. Natl. Cancer Inst. 88, 994-999 (1996).
12. Sparreboom, A. et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA 94, 2031-2035 (1997).
13. Van asperen, J., Van Tellingen, O., Van der Valk, M.A., Rozenhart, M. & Beijnen, J.H. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin a. Clin. Cancer Res. 4, 2293-2297 (1998).
14. Bardelmeijer, H.A. et al. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin. Cancer Res. 6, 4416-4421 (2000).
15. Van Tellingen, O. Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. Invest. New Drugs 22, 219-229 (2004).
16. Meerum Terwogt, J.M., Beijnen, J.H., Ten Bokkel Huinink, W.W., Rosing, H. & Schellens, J.H. Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet 352, 285 (1998).
17. Malingré, M.M. et al. a phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin a. Cancer Chemother. Pharmacol. 47, 347-354 (2001).
18. Malingré, M.M. et al. Phase I and pharmacokinetic study of oral paclitaxel. J. Clin. Oncol. 18, 2468-2475 (2000).
19. Malingré, M.M. et al. The efect of diferent doses of cyclosporin a on the systemic exposure of orally administered paclitaxel. Anticancer Drugs 12, 351-358 (2001).
20. Helgason, H.H. et al. Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer. Br. J. Cancer 95, 794-800 (2006).
21. Kruijtzer, C.M. et al. Weekly oral paclitaxel as frst-line treatment in patients with advanced gastric cancer. Ann. Oncol. 14, 197-204 (2003).
22. Kruijtzer, C.M. et al. Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 20, 4508-4516 (2002).
23. Meerum Terwogt, J.M. et al. Coadministration of oral cyclosporin a enables oral therapy with paclitaxel. Clin. Cancer Res. 5, 3379-3384 (1999).
24. Bardelmeijer, H.A., Ouwehand, M., Malingré, M.M., Schellens, J.H., Beijnen, J.H. & van Tellingen, O. Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut. Cancer Chemother. Pharmacol. 49, 119-125 (2002).
25. Malingré, M.M. et al. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients. Br. J. Cancer 85, 1472-1477 (2001).
26. Britten, C.D. et al. Oral paclitaxel and concurrent cyclosporin a: targeting clinically relevant systemic exposure to paclitaxel. Clin. Cancer Res. 6, 3459-3468 (2000).
27. De jonge, M.E., Huitema, A.D., Schellens, J.H., Rodenhuis, S. & Beijnen, J.H. Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL. Br. J. Clin. Pharmacol. 59, 325-334 (2005).
28. Malingré, M.M., Ten Bokkel Huinink, W.W., Duchin, K., Schellens, J.H. & Beijnen, J.H. Pharmacokinetics of oral cyclosporin a when co-administered to enhance the oral absorption of paclitaxel. Anticancer Drugs 12, 591-593 (2001).
29. Wils, P. et al. Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem. Pharmacol. 48, 1528-1530 (1994).
30. Bardelmeijer, H.A. et al. Low systemic exposure of oral docetaxel in mice resulting from extensive frst-pass metabolism is boosted by ritonavir. Cancer Res. 62, 6158-6164 (2002).
31. Schinkel, A.H. et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. USA 94, 4028-4033 (1997).
32. Malingré, M.M. et al. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J. Clin. Oncol. 19, 1160-1166 (2001).
33. Huisman, M.T., Smit, J.W., Wiltshire, H.R., Hoetelmans, R.M., Beijnen, J.H. & Schinkel, A.H. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol. Pharmacol. 59, 806-813 (2001).
34. Oostendorp, R.L. et al. Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors. Clin. Cancer Res. 15, 4228-4233 (2009).
35. Hellriegel, E.T., Bjornsson, T.D. & Hauck, W.W. Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin. Pharmacol. Ther. 60, 601-607 (1996).
36. Malingré, M.M. et al. Co-administration of GF120918 signifcantly increases the systemic exposure to oral paclitaxel in cancer patients. Br. J. Cancer 84, 42-47 (2001).
37. Van Herwaarden, A.E. et al. Knockout of cytochrome P450 3a yields new mouse models for understanding xenobiotic metabolism. J. Clin. Invest. 117, 3583-3592 (2007).